InvestSMART

Tetratherix Limited (ASX: TTX) - Announcements

Current share price for TTX : $5.500 0.15 (2.80%)+

ASX company news and announcements for Tetratherix Limited (TTX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Tetratherix Limited (TTX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Tetratherix Limited (TTX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Tetratherix Limited (TTX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$162 Proposed issue of securities - TTX 28 May 2026 9:23AM $6.810 $5.500 fallen by 19.24%
$162 Successful Completion $15M Placement 28 May 2026 9:22AM $6.810 $5.500 fallen by 19.24%
$162 Trading Halt 26 May 2026 9:29AM $6.810 $5.500 fallen by 19.24%
$162 Quarterly Activities/Appendix 4C Cash Flow Report 23 Apr 2026 9:26AM $4.780 $5.500 risen by 15.06%
$162 Notification regarding unquoted securities - TTX 1 Apr 2026 8:20AM $4.120 $5.500 risen by 33.50%
$162 Tetratherix March Investor Presentation 17 Mar 2026 8:30AM $5.090 $5.500 risen by 8.06%
$162 Precision medicine franchise launch and new revenue 16 Mar 2026 8:17AM $4.160 $5.500 risen by 32.21%
$162 Tutelix Update 10 Mar 2026 9:21AM $3.810 $5.500 risen by 44.36%
$162 HY FY26 Letter 24 Feb 2026 11:08AM $3.860 $5.500 risen by 42.49%
$162 Half Yearly Report and Accounts 24 Feb 2026 10:27AM $3.860 $5.500 risen by 42.49%
$162 TetraDerm Cohort 1 Results 17 Feb 2026 8:15AM $3.620 $5.500 risen by 51.93%
$162 Quarterly Activities/Appendix 4C Cash Flow Report 28 Jan 2026 8:21AM $3.830 $5.500 risen by 43.60%
$162 Initial Director's Interest Notice 21 Jan 2026 11:51AM $3.480 $5.500 risen by 58.05%
$162 Vecchione Appointment 21 Jan 2026 11:47AM $3.480 $5.500 risen by 58.05%
$162 Executed Henry Schein Agreement 19 Jan 2026 8:28AM $3.400 $5.500 risen by 61.76%
$162 TetraDerm Cohort 2 13 Jan 2026 8:25AM $3.250 $5.500 risen by 69.23%
$162 Application for quotation of securities - TTX 9 Jan 2026 8:19AM $3.250 $5.500 risen by 69.23%
$162 Notification regarding unquoted securities - TTX 5 Jan 2026 8:00PM $3.250 $5.500 risen by 69.23%
$162 Initial Director's Interest Notice 22 Dec 2025 9:04AM $3.350 $5.500 risen by 64.18%
$162 Application for quotation of securities - TTX 18 Dec 2025 5:18PM $3.360 $5.500 risen by 63.69%
$162 Final Director's Interest Notice 18 Dec 2025 11:42AM $3.400 $5.500 risen by 61.76%
$162 Director Company Secretary Appointment/Resignation 16 Dec 2025 8:21AM $3.350 $5.500 risen by 64.18%
$162 Application for quotation of securities - TTX 8 Dec 2025 4:46PM $3.800 $5.500 risen by 44.74%
$162 BioOptix Alcon Update 1 Dec 2025 8:29AM $3.850 $5.500 risen by 42.86%
$162 Notice of Escrow Release 20 Nov 2025 11:48AM $3.900 $5.500 risen by 41.03%

26 - 50 of 136 results

Page 2 of 6

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.